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Summary Heterozygous loss of the TP53 gene on chromosome arm 17p in colorectal carcinomas was
strongly associated with DNA aneuploidy (P<0.0001). This association was seen only in tumours with loss
on both 17p and 17q (P<0.001), but not for loss on 17p only. DNA near diploid (ND) carcinomas and DNA
aneuploid (AN) tumours with DNA index > 1.1 and < 1.3 had similar frequencies of TP53 gene loss (49%
and 42%, respectively), whereas AN tumours with DNA index > 1.3 had a significantly higher frequency of
TP53 gene loss (85%) (P<0.0001 and P<0.0001, respectively). There was a significant association between
loss of the TP53 gene and histological grade (P<0.01), and there tended to be an association between loss of
the TP53 gene and degree of cellular atypia (P< 0.05), with TP53 gene loss being most frequent in moderately
differentiated carcinomas, and in carcinomas with severe cellular atypia, respectively. The proportion of
tumours with loss of the TP53 gene increased significantly towards the distal part of the large bowel
(P<0.0001).
These results indicate that different genetic mechanisms may be involved in the carcinogenesis in colon and
rectum carcinomas, and in the two subsets of DNA aneuploid carcinomas. Furthermore, the data may suggest
a role for the TP53 gene in the aneuploidisation process, possibly as a 'target' for a whole chromosome loss.
The TP53 gene is known to act as a tumour suppressor gene
in several malignancies, including colorectal carcinomas (for
review, Levine et al., 1991). Inactivation of both homologous
alleles of this gene, by mutation or allele loss, may mediate
one or more steps in the carcinogenesis (Friend et al., 1988).
In article I (Meling et al., 1993), we have shown that loss of
one of the TP53 gene alleles occurred in 68% of colorectal
carcinomas, and that loss of this gene usually (in two thirds
of the tumours with TP53 gene loss) was part of a limited,
subchromosomal loss.
The purpose of a detailed classification of colorectal car-
cinomas is to stratify the patients into different prognostic
groups, and thereby enabling the identification of those
patients who should be included in a close postoperative
surveillance programme, and patients who should be offered
immediate adjuvant therapy. Since the introduction 60 years
ago, Dukes' staging has been widely accepted for the
classification of rectal carcinoma (Dukes, 1932), and later
also for classification of colonic carcinomas. The system is
still the most reliable way to assess prognosis, despite several
attempts of introducing additional tumour markers to imp-
rove estimation of clinical outcome (Rognum et al., 1987a;
Fisher et al., 1989). During the last decade, however, it has
been shown that DNA aneuploidy is a marker of a more
aggressive tumour behaviour in colorectal carcinomas, as
patients with DNA aneuploid carcinomas have a significantly
poorer prognosis than patients with DNA near diploid
tumours (Wolley et al., 1982; Rognum et al., 1987b; 1991).
As yet, the basis for this association is not known, but
specific gene alterations that are associated with DNA aneup-
loidy, may underlie the higher aggressiveness of these
tumours (Delattre et al., 1989; Meling et al., 1991a).
In this study we have examined the relationship between
loss of heterozygosity of the TP53 gene and DNA ploidy
pattern in 231 colorectal carcinomas, as well as the relation-
ship between TP53 gene loss and clinicopathological charac-
teristics of the tumours.
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Materials and methods
Patients and tumour samples
Fresh tissue samples from 231 patients with colorectal
adenocarcinomas removed during laparotomy were studied.
Clinicopathological characteristics of the patients are given in
Table I. Staging, grading, and evaluation of cellular atypia in
the tumours was performed as described previously (Meling
et al., 1991b).
Table I Clinicopathological characteristics ofthe 231 carcinomas and
patients studied
Clinicopathological
characteristics % (no)
Sex/age Male 52% (119)
< 50 years 12% (14)
> 50 years 88% (14)
mean age (range), years 68 (26-94)
Female 48% (112)
< 50 years 6% (7)
> 50 years 94% (105)
mean age (range), years 69 (24-92)
Dukes' stagea A 14% (33)
B 43% (99)
C 30% (68)
D 13% (31)
Histological gradeb
Well differentiated 5% (12)
Moderately differentiated 80% (185)
Poorly differentiated 15% (34)
Degree of cellular atypia
Slight 4% (8)
Moderate 67% (155)
Severe 29% (68)
Tumour sitec
Right colon 31% (72)
Left colon 25% (57)
Rectum 44% (102)
aAccording to the modified Dukes' classification (Dukes, 1932;
Turnbull et al., 1967). bAccording to Morson & Sobin (1976). cCarcinomas in the colon localised proximal and distal to the
mid-transversecolon, areclassified as right- and left-sided, respectively.
Rectum is defined as the distal 15 cm of the large bowel.
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Tissue preparation
Single cell suspensions were mechanically prepared either
immediately after tumour excision, or after overnight storage
in ice-cold phosphate-buffered saline (PBS), pH 7.6. The
tumour samples were minced in PBS, followed by nylon
mesh filtration (mesh pore size 70 ,sm) (Seidengazefabrik AG
Thal, Switzerland). The cells were both fixed and stored in
70% ethanol at 4°C, until flow cytometric analysis or DNA
extraction was performed.
Southern analysis
DNA extraction from tumour cells in suspensions and from
peripheral blood leucocytes was performed in a 340A Nucleic
Extractor (Applied Biosystem, Rotterdam, The Netherlands)
principally based on standard methods (Kunckel et al., 1977).
Matched tumour/normal pairs of DNA were digested with
BamHI, TaqI and Pvull, respectively, and fractionated
through 1% agarose gels. Southern blotting (Southern, 1975)
was performed as described in article I, and the DNA was
hybridised with four restriction fragment length polymor-
phism (RFLP) probes to chromosome 17, labelled with 32p
(Feinberg & Vogelstein, 1983). The probes applied were
pBHP53 (locus symbol TP53) (H0yheim et al., 1989),
pYNZ22 (D17S30) (Nakamura et al., 1988a), pTHH59
(D17S4) (Nakamura et al., 1988b), and pRMU3 (D17S24)
(Myers et al., 1988). Scoring criteria are given in detail in
article I.
Flow cytometric analysis
Analysis of nuclear DNA content was performed on ethanol
fixed single cell suspensions after nylon mesh filtration (mesh
pore size 70 m) (Seidengazefabrik AG Thal, Switzerland),
according to the method described by Crissman and Stein-
kamp (1982). The cells were incubated with RNAse,
190 tgmlh', (Boehring, Mannheim, FRG), for 30min in
dark at 20°C, and thereafter stained with the fluorochrome
propidium iodide, 17 igml-', (Sigma Chemical Co., St.
Louis, MO, USA), for 1 h on ice in dark. The emission of
red fluorescence was measured in an Ortho Cytofluorograph
50H (Ortho Instruments, Weswood, MA, USA). Mouse
spleen lymphocytes were used as an external diploid (2c)
DNA control.
Definition ofaneuploidy
The nuclear amount of DNA was expressed as a DNA index,
giving the ratio between the mean DNA content of the cell
population examined and the mean DNA content of the
diploid reference cells (Hiddeman et al., 1984). The peak in
the histogram representing cells with the lowest DNA content
was confirmed to represent DNA diploid cells (Meling et al.,
1991b). A tumour was classified as DNA aneuploid when a
second distinct population ofGI cells was present, and had a
DNA index > 1.10 (Figure 1) (Kirkhus et al., 1988; Meling
et al., 1991b). Otherwise the tumour was defined as DNA
near diploid. For the purpose of discussing DNA indices in
relation to biological relevant classifications, the tumours
were also separated according to a DNA index of 1.3, and
tumours with DNA index > 1.1 but < 1.3 were denoted
moderately DNA aneuploid, and tumours with DNA index
> 1.3, highly DNA aneuploid carcinomas.
Statistical analysis
Differences in distributions were calculated by the chi-square
test using Yates correction when expected value(s) was less
than 5. Due to multiple independent comparisons, P-values
less than 0.01 were considered to denote statistically
significant differences.
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Figure 1 a Typical DNA histogram from one DNA near diploid carcinoma. The histogram shows a single near diploid cell
population (2c) and its corresponding G2 fraction (4c). b Typical DNA histogram from one DNA aneuploid carcinoma. The first
peak represents a diploid cell population (2c), and the second an
DNA aneuploid cell population (AN) (DNA index = 1.6). The
two smaller peaks to the right represent cell clumping and the G2 fraction of the DNA aneuploid cell population, respectively.
Results
Genetic alterations on chromosome 17
One hundred and eighty-nine cases (82%, 189/231) were heterozygous (informative) for polymorphisms on both arms of chromosome 17, i.e. for at least one locus on each chromosome arm. In the following, the results are given as
number of cases in relation to the total of these 189 infor-
mative cases. Loss of heterozygosity on chromosome arm 17p was demonstrated in 68% (129 cases), and allele am- plification in 8% (15 cases). Loss on chromosome arm 17q
was demonstrated in 34% (64 cases), and amplification in 15% (29 cases). Forty-one per cent of the tumours had loss restricted to 17p (77 cases), 28% had loss on both 17p and 17q (52 cases), and 6% had loss restricted to 17q (12 cases). Further details on these alterations, as well as on the inter- relation among the genetic alterations on chromosome 17,
are given in article I.
Chromosome 17 alterations andDNAploidypattern
One hundred and forty-nine of the 231 carcinomas analysed (65%) had aneuploid DNA pattern. Of the 189 carcinomas informative at both chromosome 17 arms, 122 (65%) were
DNA aneuploid (Table II). The relationship between changes
on chromosome 17 and DNA ploidy pattern in the 189
tumours informative at both chromosome 17 arms are given in Table II. Loss of chromosome 17 was significantly associated with DNA aneuploidy (P<0.001). This associa-
tion was only seen for loss involving both 17p and 17q, thus
most likely the whole chromosome, (P<0.001), but not for
loss only on 17p, or for loss only on 17q (Table II). Amplification on 17q tended to be associated with DNA
aneuploidy (P<0.05) (Table II). Tumours with no alterations
detected on chromosome 17 were much more frequent DNA
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Table II Relation between chromosome 17 alterations and DNA ploidy pattern in
the 189 colorectal carcinomas infomative at both chromosome 17 arms
% (no.) of tumours with: Sign.
Alteration Chromosome arm AN (122)a ND (67)a Level
Loss on 17 (either arm) 83% (101) 60% (40) P<0.001
17p 79% (96) 49% (33) P<0.0001
17q 40% (49) 22% (15) P<0.05
both 17p and 17q 36% (44) 12% (8) P<0.001
Loss only on 17p 43% (52) 37% (25) n.s.
17q 4% (5) 10% (7) n.s.
Amplification on 17p 11% (13) 3% (2) n.s.
17q 20% (24) 7% (5) P<0.05
No chromosome 17 alteration 15% (18) 40% (27) P<0.0001
'AN = DNA aneuploid carcinomas, ND = DNA near diploid carcinomas.
near diploid than DNA aneuploid (P<0.0001) (Table II).
The DNA indices of the total 149 DNA aneuploid
tumours showed a bimodal distribution, with the majority of
tumours (85%, 126/149) having a DNA index > 1.3, and the
remaining DNA aneuploid tumours (15%, 23/149) had DNA
indices ) 1.1 and < 1.3 (Figure 2). The distribution of
chromosome 17 alterations was analysed in these two subsets
of DNA aneuploid tumours among the 189 tumours infor-
mative at both chromosome 17 arms. The tumours with
DNA index > 1.1 and <1.3 (moderately DNA aneuploid)
had a similar frequency of loss on 17p as the DNA near
diploid carcinomas (8/19 = 42% versus 33/67 = 49%, n.s.).
Of the tumours with DNA index > 1.3 (highly DNA aneu-
ploid), 85% (88/103) had loss on 17p, which is significantly
more frequent than in both moderately DNA aneuploid
tumours (P<0.0001) and DNA near diploid and moderately
DNA aneuploid tumours pooled together (P<0.0001).
Chromosome 17 alterations and clinicopathological
characteristics
There was no significant association between loss on 17p and
Dukes' stage (Table III). Amplification on 17q tended to be
associated with Dukes' stage, with increasing frequency of
amplification in more advanced Dukes' stages (P<0.05)
(Table III). A significant association between loss on 17p and
histological grade was found (P<0.01) (Table III), loss on
17p being more frequent in the moderately differentiated
carcinomas compared with the well - (P<0.05) and with the
poorly differentiated ones (P<0.05), respectively. Increase in
proportion of tumours with loss on 17p tended to be
associated with increase in degree of cellular atypia
(P<0.05) (Table III). When the tumours were separated
according to DNA ploidy pattern, this tendency was found
in the DNA aneuploid tumour group (P<0.05), but not in
the DNA near diploid tumour group (data not shown).
A significant association was found between loss on 17p
and site of the tumour (for all sites, P<0.0001) (Table IV);
loss on 17p being more frequent in tumours located in retum
than in the left (P<0.01) and the right,colon (P<0.0001),
respectively. Since also DNA ploidy pattern tended to be
associated with tumour site (Table IV), the tumours were
separated according to DNA ploidy pattern. A significant
association between loss on 17p and tumour site was found
only in the DNA near diploid tumour group (P<0.0001),
but not in the DNA aneuploid tumour group (Table IV).
No significant association was found between loss on 17p
and sex, as 66% (65 of 98) of tumours in female patients had
loss on 17p, compared with 70% (64 of 91) of tumours in
male patients (n.s.). The patients were separated according to
age of less than 50 years, and of 50 years or more, respec-
tively. There tended to be more female patients of less than
50 years that had tumours with loss on 17p (7/7, 100%),
compared with female patients of 50 years or more (57/91,
63%) (P<0.05), whereas no such difference was found for
male patients (data not shown).
E
......
E a
Z -_
10
0
1.0 1.2 1.4 a 1.6 1I.- 2-.0 2,2 324 2.6 2.8 3.0
1.1 .1.3 1.5 1.7 1.9 2.1 2.3 2.52.7 2.9
DNA-index
Figure 2 Distribution of the 231 carcinomas according to DNA
index.
Discussion
We have shown that loss of heterozygosity as detected by
either of the probes used on chromosome arm 17p can be
regarded as loss of the TP53 gene in colorectal carcinomas.
Loss on 17p can therefore be used synonymously with loss of
the TP53 gene. Loss of the TP53 gene was most frequently
part of a limited, subchromosomal loss. This is further dis-
cussed in article I. In this study, a highly significant associa-
tion could be demonstrated between loss of the TP53 gene
and DNA aneuploidy. However, this association was seen
only when the loss involved large parts of (most likely the
whole) chromosome, but not when loss was found only on
17p. An association between loss on chromosome arm 17p
and DNA aneuploidy has previously been reported (Delattre
et al., 1989), but whether this loss was 'part of a sub-
chromosomal loss, or involved the whole chromosome was
not discussed by these authors. Based on our findings, we
conclude that only tumours with loss of the whole
chromosome 17 are responsible for the association between
loss of the TP53 gene and DNA aneuploidy. Loss of the
whole chromosome 17 may result from mitotic non-
disjunction (Cavenee et al., 1983). Our findings suggest a role
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Table III Clinicopathological characteristics ofthe 189informative tumoursaccording to
loss on 17p
Clinico- % (no.) oftumours/no. ofinformative cases
pathological Sign. Sign.
characteristics Loss on 17p level Amplif. on 17q level
Dukes' stage A 64% (18/28) 14% (4/28)
B 69% (59/86) 8% (7/86)
C 66% (33/50) 22% (11/50)
D 76% (19/25) n.s.a 28% (7/25) p<O.05a
Histological grade
Well differentiated 40% (4/10) 0% (0/10)
Moderately diff. 73% (109/149) 18% (27/149)
Poorly differentiated 53% (16/30) P<0.05a 7% (2/30) n.s.a
Degree of cellular atypia
Slight 43% (3/7) 14% (1/7)
Moderate 65% (83/128) 17% (22/128)
Severe 79% (43/54) P<0.05a 11% (6/54) n.s.a
afor all subgroups.
Table IV The relations ofloss on 17p and DNA aneuploidy to site oftumour in the 189
colorectal carcinomas informative on both chromosome 17 arms
Tumour site
% (no.) oftumours/no. ofinformative cases Sign.
Alteration Right colona Left colona Rectuma levelb
Loss on 17p 50% (29/58) 62% (29/47) 84% (71/84) P<0.0001
DNA aneuploidy 52% (30/58) 62% (29/47) 75% (63/84) P< 0.05
Loss on 17p in 77% (23/30) 69% (20/29) 84% (53/63) n.s.
AN tumoursc
Loss on 17p in 21% (6/28) 50% (9/18) 86% (18/21) P<0.0001
ND tumoursc
asee Table I. bfor all sites. CAN = DNA aneuploid, ND = DNA near diploid.
for the TP53 gene loss in the aneuploidisation process, pos-
sibly as a 'target' of loss of the whole chromosome 17. We
cannot exclude that DNA aneuploidy only is associated with
unspecific chromosome 17 monosomy in colorectal car-
cinomas, and not with loss of the TP53 gene in particular.
However, since our results do not indicate any additional
tumour suppressor gene(s) on chromosome 17 involved in
colorectal carcinogenesis (as discussed in article I), we suggest
that the 'target' of loss of the whole chromosome 17 in
colorectal carcinomas most likely is the TP53 gene.
We have previously reported loss on chromosome lp in
22% of 180 colorectal carcinomas (Meling et al., 199la). This
is in agreement with other studies (Vogelstein et al., 1988;
Leister et al., 1990; Couturier-Turpin et al., 1992), and sug-
gets the existence of an essential genetic region on
chromosome 1 involved in colorectal carcinogenesis in a
subset of tumours. The loss on chromosome lp was also
significantly associated with DNA aneuploidy, and a similar
association was found for loss on chromosome 2p (Meling et
al., 1991a). Based on these observations, we postulate that
DNA aneuploid tumours have lost more tumour suppressor
genes than DNA near diploid tumours.
DNA aneuploidy, as measured by flow cytometry, is by
consensus defined as the existence of one or more extra cell
population(s) with aberrant cellular DNA content (Hid-
deman et al., 1984). This definition, however, may end up
with a distinction between DNA diploid and DNA aneuploid
cells as being a matter ofmethodology and a question related
to the resolution of DNA measurements, rather than
reflecting biological differences. Thus, pooling together DNA
aneuploid tumours with very low DNA indices and tumours
with high DNA indices, may preclude the revelation of
significant biological associations. In our study, we have
denoted tumours with DNA index > 1.1 as DNA aneuploid.
The distribution of DNA indices of the 149 DNA aneuploid
tumours showed a bimodal pattern, with the majority of
tumours having a DNA index ) 1.3 (Delattre et al., 1989).
The findings of significantly different proportions of tumours
with TP53 gene loss in the moderately and highly DNA
aneuploid carcinomas, may reflect different pathways in the
carcinogenesis in these two subsets of tumours. This would
be in agreement with a recently presented theory on sequen-
tial DNA aneuploidisation during colorectal carcinogenesis
(Giaretti & Santi, 1990).
Allele amplification on 17q tended to be associated with
increase in tumour spread (Dukes' stage). Chromosome 17
may share similarities with chromosome 1 in colorectal car-
cinomas, since both chromosomes have a high frequency of
loss on the short chromosome arm, and both have
amplification on the long arm. The amplication demonstrated
on chromosome arm 17q may be, therefore, a late event in
the development of these tumours, as has been interpreted
for this genetic change on chromosome arm lq (Atkin, 1986;
Couturier-Turpin et al., 1992).
A significant association could be demonstrated between
TP53 gene loss and histological differentiation, and there also
tended to be an association between TP53 gene loss and
degree of cellular atypia. Thus, the TP53 gene may be one of
the factors associated with morphological transformation of
the mucosa cells during colorectal carcinogenesis. Further-
more, since DNA aneuploidy is also associated with increas-
ing degree of cellular atypia (Meling et al., 1991b), tumours
with severe atypia may have a higher frequency of genetic
alterations, and, therefore, possibly higher genetic instability
(Nowell, 1982), than tumours with less degree of cytological
aberrations.
The proportion of tumours with loss of the TP53 gene as
well as with DNA aneuploidy increased markedly towards
the distal part of the large bowel. This observation might
reflect different carcinogenic mechanisms for carcinomas of
the colon and rectum, in agreement with earlier reports
(Delattre et al., 1989; Bufill, 1990). The cluster of DNA near
diploid carcinomas without loss of the TP53 gene in the right
colon is interesting, since hereditary non-polyposis colon
cancers are also most frequently located in this part of the
colon (Lynch et al., 1985), and since it has recently been
reported that the majority of hereditary non-polyposis car-
cinomas is DNA near diploid (Kouri et al., 1990; Frei et al.,TP53 GENE LOSS, DNA ANEUPLOIDY, AND TUMOUR VARIABLES 97
1992). Our observations may, therefore, indicate that the
TP53 gene is not the gene associated with this syndrome.
Studies are under way in our laboratory to further clarify
this question. Both the DCC gene on chromosome 18
(Fearon et al., 1990) and the APC gene on chromosome 5
(Groden et al., 1991; Nishisho et al., 1991) have previously
been excluded as the gene responsible for hereditary non-
polyposis cancer (Peltomaki et al., 1992). Furthermore, the
DNA indices reported for the hereditary non-polyposis car-
cinomas were mainly between 1.0 and 1.3 (Kouri et al.,
1990), further emphasising the importance of questioning
where to draw the biologically relevant border between DNA
near diploid and DNA aneuploid carcinomas.
We have recently demonstrated that 30% of colorectal
carcinomas have allele amplification within the Retinoblas-
toma (Rbl) gene (Meling et al., 1991a), suggesting a role for
this gene in carcinogenesis in the colorectum. The tumours
with loss of the TP53 gene more frequently had Rbl gen
amplification than tumours without TP53 gene loss (P<
0.01, data not shown). However, this may be explained by
the association between TP53 gene loss and DNA aneuploidy
and between Rbl gene amplification and DNA aneuploidy,
respectively, since no association could be demonstrated
between TP53 gene loss and Rbl gene amplification in the
DNA near diploid and the DNA aneuploid tumour group,
respectively (data not shown).
We conclude that DNA aneuploidy may not represent a
causal factor in carcinogenesis, but rather a marker of under-
lying genetic changes, as for instance loss of tumour suppres-
sor genes. Since TP53 gene loss was associated both with
DNA aneuploidy, with more deranged cytological features,
as well as with left sided tumours, a role for this gene also
for tumour aggressiveness is suggested. Further studies re-
garding this question are in progress in our laboratory.
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